Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.

ABSTRACT:

Objectives

Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%-80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here, we evaluate GEP analysis outside clinical trials, aiming to improve clinical risk assessment of multiple myeloma (MM) patients.

Methods

A total of 155 bone marrow samples from MM patients were collected from which RNA was analyzed by microarray. Sixteen previously developed GEP-based markers were evaluated, combined with survival data, and studied using Cox proportional hazard regression.

Results

Gene expression profiling-based markers SKY92 and the PR-cluster were shown to be independent prognostic factors for survival,

SUBMITTER: Chen YT 

PROVIDER: S-EPMC9290833 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature